RESUMEN
In the current study, via utilizing H5L (H5L = 2,4-di(3',5'-dicarboxylphenyl)benzoic acid), the symmetrical rigid polycarboxylic acid ligand with V-shape geometry, two new coordination polymers containing Cu(II) and Co(II) have been produced, and their chemical formulae respectively are {[Co5(L)2(H2O)12]·6H2O} n (1) and {[H2N(Me)2][Cu2(L)(H2O)]·DMF·H2O} n (2), leading to a variety kinds of coordination patterns of H5L and multifunctional skeletons. Their inhibitory activity on the insulin resistance of colon cancer patients was assessed. In addition, the detailed mechanism of the compound was also investigated. Firstly, the detection of enzyme-linked immunosorbent assay was carried out and the Tumor Necrosis Factor-α (TNF-α) level and the Interleukin-1ß (IL-1ß) level was detected. Then, the glucose concentration was determined with blood glucose meter. Next, the insulin receptor expression levels of ß cells were determined with the real time reverse transcription-polymerase chain reaction assay. Ultimately, the cytotoxicity of compounds 1 and 2 was determined with Cell Counting Kit-8 assay.
Asunto(s)
Neoplasias del Colon/metabolismo , Complejos de Coordinación/farmacología , Hipoglucemiantes/farmacología , Resistencia a la Insulina/fisiología , Polímeros/farmacología , Glucemia/metabolismo , Cobalto/química , Cobalto/toxicidad , Neoplasias del Colon/sangre , Neoplasias del Colon/fisiopatología , Complejos de Coordinación/química , Complejos de Coordinación/toxicidad , Cobre/química , Cobre/toxicidad , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/toxicidad , Interleucina-1beta/metabolismo , Polímeros/química , Polímeros/toxicidad , Receptor de Insulina/metabolismo , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Resistance to doxorubicin (DOX) is the most common clinical problem in breast cancer therapy, and the underlying molecular mechanism remains to be investigated. MicroRNAs (miRNAs) exhibit important regulatory functions in various malignant tumors including breast cancer. The aim of the present study was to find the relationship between miR-222 and DOX resistance. We found that miR-222 was highly expressed in patients' serum and DOX-resistant cell line MCF-7-R and that miR-222 could promote proliferation and migration of breast cancer cells. Our results also showed that inhibition of miR-222 in MCF-7-R significantly increased Bcl-2 interacting mediator (Bim) expression both in mRNA and protein levels by using quantitative real-time PCR (qRT-PCR) and Western blot. MTT and flow cytometry suggested that lower expressed miR-222 enhanced apoptosis and decreased IC50 of MCF-7-R cells. Conversely, in MCF-7 cells transfected with miR-222 mimics, up-regulation of miR-222 was associated with decreased Bim level accompanied by less apoptosis and higher IC50 Moreover, miR-222 inhibitors reversed DOX resistance via miR-222-Bim-caspase pathway. Collectively, these data first elucidated that miR-222 could function as an oncogene and was able to reduce the sensitivity of breast cancer cells to DOX through miR-222-Bim-caspase pathway, which provided a potential target to increase DOX sensitivity in clinical breast cancer treatment.